A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CS23546 in Subjects With Advanced Tumors
Latest Information Update: 26 Apr 2024
At a glance
- Drugs CS 23546 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chipscreen Biosciences
Most Recent Events
- 21 Apr 2024 Status changed from not yet recruiting to recruiting.
- 12 Feb 2024 New trial record